Breast Cancer Hormone Therapy Can Weaken Bones: Here’s How to Protect Them

Breast cancer treatment doesn’t always end when surgery, chemotherapy, or radiation therapy is completed. For many women with hormone receptor-positive breast cancer, taking medication for several more years becomes an important part of reducing the risk of the disease returning.

Aromatase inhibitors, including anastrozole, letrozole, and exemestane, are commonly prescribed for this purpose. These medications help prevent estrogen from stimulating the growth of certain breast cancer cells. However, the same reduction in estrogen that makes aromatase inhibitors effective can also affect bone health.

Unlike joint pain or hot flashes, bone loss often develops without noticeable symptoms. A woman may feel perfectly well while gradually losing bone density. In some cases, the problem is discovered only during a routine bone density scan or after an unexpected fracture.

This is why protecting bones should be part of breast cancer care from the beginning, rather than something considered only when osteoporosis develops.

The reassuring news is that bone loss caused by aromatase inhibitors can often be reduced or managed through early screening, appropriate nutrition, physical activity, and medications that protect bone strength.

Understanding how these treatments affect the skeleton can help patients take practical steps to reduce their risk of osteoporosis and fractures while continuing essential breast cancer therapy.

Aromatase inhibitors are medications used to treat hormone receptor-positive breast cancer, a type of breast cancer in which estrogen can encourage cancer cells to grow.

After menopause, the ovaries produce very little estrogen. However, the body continues to make smaller amounts through the conversion of other hormones into estrogen by an enzyme called aromatase.

Aromatase inhibitors block this enzyme, significantly reducing estrogen production.

Three commonly prescribed medications include:

• Anastrozole (Arimidex): Used to reduce estrogen production and lower the risk of recurrence in certain patients with hormone receptor-positive breast cancer.
• Letrozole (Femara): Prescribed for early-stage and certain advanced hormone receptor-positive breast cancers.
• Exemestane (Aromasin): A steroidal aromatase inhibitor that lowers estrogen through a different mechanism from anastrozole and letrozole.

These medications are frequently used in postmenopausal women. They may also be prescribed to premenopausal women when ovarian function is medically suppressed.

Depending on the cancer characteristics and individual treatment plan, endocrine therapy may continue for five years or longer.

Although aromatase inhibitors provide important benefits in reducing breast cancer recurrence, their effects on estrogen can accelerate bone loss and increase fracture risk. [1,2]

To understand aromatase inhibitor-associated bone loss, it helps to know that bone is not a fixed structure.

Even in adulthood, the skeleton is constantly renewing itself. Specialized cells remove older bone tissue, while other cells produce new bone.

Under normal circumstances, these processes remain reasonably balanced, helping maintain bone strength.

Estrogen plays an important role in controlling this balance. It helps limit excessive bone breakdown and supports the maintenance of healthy bone tissue.

When estrogen levels decrease during menopause, bone breakdown can begin to occur faster than bone formation.

Aromatase inhibitors reduce estrogen levels further, potentially accelerating this process.

Over time, the body may lose more bone than it replaces. This can result in lower bone mineral density, deterioration of bone structure, and an increased likelihood of fractures.

Research summarized in the United Kingdom’s 2024 osteoporosis guidelines indicates that aromatase inhibitor therapy in postmenopausal women can lead to average bone loss of approximately 1% to 3% annually at sites containing substantial trabecular bone.

Bone loss may be considerably greater in younger women experiencing treatment-induced ovarian suppression. These figures are averages, however, and individual experiences vary. [3]

One of the most concerning aspects of osteoporosis is that it usually develops silently.

Bones do not necessarily hurt as they lose density. A person may continue walking, exercising, and performing daily activities without realizing their fracture risk is increasing.

Pain is more likely to develop when a weakened bone fractures or when another musculoskeletal problem is present.

This makes bone density monitoring particularly valuable during long-term aromatase inhibitor treatment.

All three commonly prescribed aromatase inhibitors can contribute to decreased bone mineral density.

Anastrozole, letrozole, and exemestane work through slightly different mechanisms, but their shared effect is a substantial reduction in estrogen.

Because estrogen plays a protective role in bone health, each medication can increase the risk of osteoporosis and fractures.

Anastrozole is widely used in postmenopausal women with hormone receptor-positive breast cancer.

Long-term treatment can accelerate bone turnover and reduce bone density, particularly in women who already have low bone mass.

Patients taking anastrozole may require periodic bone density scans and, depending on their fracture risk, treatment to preserve bone strength.

Letrozole also significantly suppresses estrogen production.

Patients receiving letrozole may develop progressive bone loss, especially when treatment extends over several years.

Age, prior fractures, baseline bone density, and other medical conditions influence the degree of risk.

Exemestane is a steroidal aromatase inhibitor, but it can still contribute to osteoporosis and fractures.

Although studies have examined differences in bone effects among these medications, none should be assumed to be free of skeletal risk.

There is no single aromatase inhibitor that guarantees protection against bone loss. Bone health monitoring remains important regardless of which medication is prescribed. [1,2]

Bone loss may begin within the first year of treatment, even when the patient has no symptoms.

The rate depends on several factors, including age, menopausal status, initial bone density, other medical conditions, and whether additional cancer treatments affect hormone levels.

Women who already have osteopenia or osteoporosis before starting aromatase inhibitors may face a greater risk of clinically significant bone loss.

For some patients, bone density decreases gradually over several years. Others experience a more substantial decline early in treatment.

Longer treatment duration can also increase cumulative fracture risk.

The updated 2025 international joint position statement on aromatase inhibitor-associated bone loss emphasizes the need for individualized fracture risk assessment and continued monitoring, particularly when treatment extends beyond five years. [1]

This is why physicians commonly recommend evaluating bone health before or near the beginning of aromatase inhibitor therapy.

Osteopenia and osteoporosis both describe reduced bone density, but they represent different degrees of bone loss.

Osteopenia means that bone density is lower than normal but has not reached the diagnostic threshold for osteoporosis.

Osteoporosis is a condition in which bones become sufficiently weak that fractures are more likely, sometimes after a minor fall or everyday movement.

A person with osteopenia can still have an elevated fracture risk, particularly when taking medication that accelerates bone loss.

A person with osteoporosis faces a greater risk of fragility fractures, especially involving the spine, hip, and wrist.

Not everyone with osteopenia progresses to osteoporosis. However, regular monitoring and appropriate preventive measures become particularly important when additional risk factors are present.

A bone density scan is one of the most useful tools for identifying bone loss before a fracture occurs.

The test, commonly called a DEXA scan, uses low-dose X-rays to measure bone mineral density, usually at the hip and lower spine.

It is generally quick, painless, and noninvasive.

Patients beginning aromatase inhibitor therapy should have their fracture risk assessed, including bone density measurement where appropriate.

A baseline scan allows clinicians to determine whether bones are already weakened before treatment begins.

It also provides a reference point for later comparisons.

Without an initial measurement, it can be difficult to determine how much bone density has changed during therapy.

Bone density results in postmenopausal women are commonly reported using a T-score, which compares an individual’s bone density with that of a healthy young adult.

In general:

• A T-score of -1.0 or higher indicates normal bone density.
• A T-score between -1.0 and -2.5 indicates low bone density, also called osteopenia.
• A T-score of -2.5 or lower is consistent with osteoporosis.

These categories help clinicians assess skeletal health, but treatment decisions also depend on age, medical history, previous fractures, and other risk factors.

Importantly, patients taking aromatase inhibitors may qualify for bone-protective treatment before their bone density reaches the standard osteoporosis threshold. [4]

The frequency of bone density monitoring depends on individual risk.

Updated international guidance recommends monitoring bone mineral density and fracture risk approximately every one to two years for certain lower-risk women taking aromatase inhibitors.

Patients receiving bone-protective medications may undergo monitoring at different intervals, commonly around every two years.

Those experiencing rapid bone loss or having additional fracture risk factors may require closer assessment.

The oncologist or osteoporosis specialist should determine the appropriate schedule. [1]

Not every patient receiving an aromatase inhibitor will experience the same degree of bone loss. Some maintain relatively stable bone density, while others develop significant changes that require treatment.

Several factors can increase the likelihood of osteoporosis and fractures:

• Being older, particularly after menopause.
• Having osteopenia or osteoporosis before starting treatment.
• Experiencing a previous fracture after a minor fall or injury.
• Having a parent who sustained a hip fracture.
• Having a low body weight or body mass index.
• Receiving long-term corticosteroid medications.
• Smoking or consuming excessive alcohol.
• Having inadequate calcium or vitamin D intake.
• Living with conditions that affect nutrient absorption or bone metabolism.
• Experiencing early menopause or treatment-induced ovarian suppression.

Fall risk also matters. Poor balance, muscle weakness, vision problems, and certain medications can increase the likelihood of injuries, even when bone density is only moderately reduced.

Physicians may use a fracture risk assessment tool to estimate the probability of experiencing an osteoporotic fracture over the next ten years.

However, commonly used risk calculators may underestimate fracture risk associated with aromatase inhibitor therapy. Clinical judgment and bone density measurements remain essential. [1,3]

Preventing osteoporosis during breast cancer treatment involves more than taking a calcium supplement.

The most effective approach considers nutrition, physical activity, fall prevention, medical monitoring, and medication when necessary.

Calcium is a major structural component of bones. When dietary calcium is insufficient, the body may draw calcium from the skeleton to maintain normal blood levels.

Over time, inadequate intake can contribute to reduced bone strength.

Many women aged 51 and older are advised to obtain approximately 1,200 milligrams of calcium daily from food and supplements combined. Individual requirements may differ based on age, medical conditions, and dietary intake. [5]

Calcium-rich foods include milk, yogurt, cheese, calcium-fortified plant-based beverages, calcium-set tofu, and certain leafy green vegetables.

For patients who avoid dairy products, fortified foods and other calcium-rich alternatives can help meet daily requirements.

It is generally preferable to obtain calcium through a balanced diet whenever possible. Supplements may be needed when dietary intake falls short.

However, taking more calcium than necessary does not provide additional protection and may increase the risk of adverse effects in some individuals.

Patients with kidney disease, a history of kidney stones, or abnormal calcium levels should consult their healthcare professional before starting supplementation.

Vitamin D helps the body absorb calcium and supports normal bone mineralization and muscle function.

Without sufficient vitamin D, the body may struggle to use dietary calcium effectively.

Vitamin D can be obtained through certain foods, fortified products, supplements, and sunlight exposure.

However, relying exclusively on sunlight may not provide adequate vitamin D for everyone.

Some adults with osteoporosis or increased fracture risk are advised to take approximately 800 to 1,000 international units of vitamin D daily, although the appropriate amount depends on individual circumstances.

A healthcare professional may recommend blood testing when vitamin D deficiency is suspected or when bone-protective treatment is being planned.

High-dose vitamin D should not be taken without medical guidance. Excessive supplementation can cause elevated calcium levels and other complications.

Exercise is an important part of maintaining bone and muscle health during breast cancer treatment.

Weight-bearing activities place controlled mechanical demands on the skeleton, helping support bone strength.

Walking, stair climbing, dancing, and other activities performed while supporting body weight may be useful, depending on a patient’s physical condition.

Resistance training is equally important because stronger muscles help support movement, balance, and stability.

Appropriate activities may include:

• Walking regularly at a comfortable pace.
• Performing supervised resistance exercises.
• Using resistance bands or light weights.
• Practicing balance exercises to reduce falls.
• Strengthening the hips, legs, back, and core muscles.

Exercise programs should be adapted for patients with osteoporosis, recent fractures, significant neuropathy, or other treatment-related limitations.

Those with known spinal osteoporosis may need to avoid loaded forward bending, forceful twisting, or other movements that increase vertebral fracture risk.

Patients with bone metastases require an individualized exercise plan developed with their cancer care team.

Exercise can help maintain physical function and reduce falls, but it does not replace prescription osteoporosis treatment when fracture risk is high.

Smoking is associated with poorer bone health and an increased risk of fractures.

It may interfere with normal bone remodeling and can compound the effects of aging and hormonal changes.

Excessive alcohol intake is another concern because it may adversely affect bone metabolism and increase the likelihood of falls.

Avoiding smoking and limiting alcohol consumption support both bone health and overall cancer survivorship.

Patients who need assistance quitting smoking can ask their healthcare team about counseling and evidence-based cessation treatments.

Fall prevention is especially important for patients who already have low bone density.

A minor fall that causes only bruising in someone with healthy bones may result in a hip or wrist fracture in someone with osteoporosis.

Simple changes can reduce avoidable risks.

Keeping walkways clear, improving lighting, securing loose rugs, wearing supportive footwear, and installing grab bars where needed may make the home safer.

Patients experiencing dizziness, numbness in the feet, or balance difficulties should discuss these symptoms with their healthcare team.

Balance training and physical therapy can be particularly helpful when muscle weakness or chemotherapy-related nerve problems affect walking.

Lifestyle changes are valuable, but they may not provide sufficient protection for every patient.

Women with osteoporosis, substantial bone loss, previous fragility fractures, or other important risk factors may require medications specifically designed to preserve bone strength.

Two major treatment options are bisphosphonates and denosumab.

The 2025 international recommendations support bone-protective therapy for selected patients at increased risk, including those with sufficiently low bone density or multiple clinical risk factors. [1]

Bisphosphonates reduce the activity of cells responsible for breaking down bone.

By slowing excessive bone resorption, they help preserve or improve bone mineral density.

Common medications include:

• Alendronate
• Risedronate
• Ibandronate
• Zoledronic acid

Some bisphosphonates are taken orally, while others are administered intravenously.

Zoledronic acid is frequently considered in breast cancer care because it can preserve bone density and, in selected patients, may also provide benefits related to breast cancer outcomes.

However, treatment selection depends on cancer characteristics, menopausal status, bone density, kidney function, and other clinical considerations.

Oral bisphosphonates require careful administration instructions. Patients are usually advised to take them with plain water on an empty stomach and remain upright for a specified period to reduce irritation of the esophagus.

Intravenous bisphosphonates may cause temporary flu-like symptoms after treatment.

Kidney function should be evaluated before certain bisphosphonates are prescribed.

Rare but important complications include osteonecrosis of the jaw and atypical femoral fractures, particularly with prolonged exposure. Dental health and individual risk factors should be reviewed before starting treatment.

Denosumab is another medication used to prevent excessive bone breakdown.

It works by blocking a protein involved in activating the cells that remove bone tissue.

For osteoporosis prevention during aromatase inhibitor therapy, denosumab is commonly administered as an injection every six months when prescribed at the relevant bone-protection dose.

Its ability to reduce fractures in women receiving aromatase inhibitors has been demonstrated in clinical research.

In the ABCSG-18 randomized trial, involving more than 3,400 postmenopausal women receiving aromatase inhibitor therapy, denosumab significantly reduced the risk of clinical fractures compared with placebo. [6]

This is particularly important because improving a bone density score is not the only goal of treatment. The more meaningful objective is preventing fractures that can affect mobility, independence, and quality of life.

Nevertheless, denosumab requires careful medical supervision.

Low blood calcium must be corrected before treatment, and adequate calcium and vitamin D intake is important.

In 2024, the United States Food and Drug Administration added a boxed warning concerning severe hypocalcemia in patients with advanced chronic kidney disease receiving denosumab, particularly those undergoing dialysis. [7]

Another essential consideration is that denosumab should not be stopped or significantly delayed without a medical plan.

Stopping treatment can lead to a rebound increase in bone turnover and an elevated risk of vertebral fractures. Physicians commonly arrange follow-on antiresorptive treatment when denosumab is discontinued.

Patients should discuss treatment duration and discontinuation plans before starting therapy.

Bone density can sometimes improve during aromatase inhibitor treatment, particularly when effective bone-protective medication is introduced.

Bisphosphonates and denosumab can reduce bone breakdown, and many patients experience stabilization or increases in measured bone mineral density.

However, improvement does not necessarily mean that bones have returned completely to their previous strength.

Bone structure, age, previous fractures, and underlying medical conditions influence recovery.

Patients who begin treatment with osteoporosis may require continued monitoring and long-term management, even if their bone density improves.

The aim is to preserve skeletal strength, reduce fracture risk, and enable patients to continue appropriate breast cancer treatment as safely as possible.

Some patients experience stabilization or partial recovery of bone density after completing aromatase inhibitor therapy.

When estrogen suppression from the medication ends, the rate of bone loss may decrease.

However, recovery is not always complete.

Age-related bone loss continues after menopause, and patients who developed osteoporosis during treatment may remain at increased fracture risk.

The degree of recovery depends on baseline bone health, treatment duration, other medical conditions, and whether bone-protective treatment was provided.

Patients should not assume that completing aromatase inhibitor therapy automatically eliminates their osteoporosis risk.

Bone density monitoring and fracture prevention may still be needed after breast cancer hormone therapy ends.

Joint pain and bone loss are related to the effects of estrogen reduction, but they are not the same condition.

Aromatase inhibitors can cause joint stiffness, muscle aches, and discomfort involving tendons and surrounding tissues.

These symptoms are often described as aromatase inhibitor-induced arthralgia.

Osteoporosis, by contrast, typically develops without noticeable pain until a fracture occurs.

A patient may experience severe joint discomfort while having relatively normal bone density. Another patient may have significant osteoporosis without any joint symptoms.

For this reason, joint pain cannot reliably indicate whether a person is losing bone.

Likewise, the absence of joint pain does not guarantee healthy bones.

Both problems deserve appropriate attention, but bone density testing is needed to assess skeletal health.

Patients who experience new or persistent focal bone pain should seek medical evaluation rather than assuming it is an ordinary aromatase inhibitor side effect.

In many cases, yes.

Developing osteopenia or osteoporosis does not automatically mean aromatase inhibitor therapy must be discontinued.

Physicians can often address bone loss through monitoring, nutritional support, exercise, and prescription medications.

For patients with significant skeletal risk, the oncology team may coordinate care with an endocrinologist or osteoporosis specialist.

Treatment decisions consider both the benefits of aromatase inhibitor therapy for breast cancer and the risks associated with further bone loss.

In selected circumstances, an oncologist may discuss alternative endocrine treatments.

However, switching hormone therapy involves considerations beyond bone health, including cancer recurrence risk and the side effects of alternative medications.

Patients should never stop anastrozole, letrozole, or exemestane independently because of a low bone density result.

A treatment plan that protects both cancer outcomes and skeletal health is often possible.

Osteoporosis may remain unnoticed for years, but certain symptoms require attention.

Sudden back pain, particularly after a minor movement or lifting activity, may indicate a vertebral compression fracture.

A noticeable reduction in height or a gradually developing hunched posture may also suggest vertebral fractures.

Pain after a minor fall, especially involving the hip or wrist, requires medical assessment.

Patients should contact their healthcare professional if they develop:

• New, persistent, or worsening back pain.
• Sudden focal bone pain after minimal activity.
• An unexplained loss of height.
• Increasing difficulty standing upright.
• Pain or inability to bear weight after a fall.

New bone pain in someone with a history of breast cancer should not automatically be attributed to osteoporosis. Other causes, including cancer-related bone disease, may need to be excluded.

Severe back pain accompanied by leg weakness, numbness, or loss of bladder or bowel control requires emergency medical evaluation.

Long-term bone protection is most effective when it becomes part of routine cancer follow-up.

Patients and clinicians can work together to establish a plan that evolves as treatment progresses.

At the beginning of aromatase inhibitor therapy, the priority is to identify existing osteoporosis risk factors and obtain an appropriate baseline bone density assessment.

During treatment, regular reviews can evaluate changes in bone density, dietary intake, exercise habits, fall risk, and medication tolerance.

Patients prescribed bisphosphonates or denosumab should follow their treatment schedule and attend recommended monitoring appointments.

Bone health may also be affected by changes in weight, mobility, other medications, and additional medical conditions.

Even after endocrine therapy is completed, patients with osteoporosis or a history of fragility fractures may require continued care.

This approach reflects an important principle in breast cancer survivorship: protecting long-term health involves managing treatment-related complications, not simply monitoring for cancer recurrence.

There is no amount of bone loss that should automatically be considered acceptable without evaluating the patient’s overall fracture risk. Research indicates that aromatase inhibitor therapy can cause average bone loss of approximately 1% to 3% annually at certain skeletal sites in postmenopausal women. The actual rate varies. Bone density scans help determine whether preventive treatment or additional monitoring is needed.

Both medications lower estrogen levels and can increase osteoporosis risk. Evidence has not established a universally preferable option for protecting bone density. The choice between anastrozole and letrozole should primarily reflect the patient’s cancer treatment needs and individual tolerance, with appropriate bone health management during therapy.

Not necessarily. Bone-protective medications are generally recommended based on bone density, previous fractures, and other risk factors. Patients at lower risk may initially be managed with physical activity, adequate nutrition, fall prevention, and regular monitoring. Those at higher risk may benefit from bisphosphonates or denosumab.

Many patients undergo monitoring approximately every one to two years, although the schedule varies according to their initial bone density, fracture risk, and whether they receive osteoporosis medication. Patients with rapidly declining bone density may require more individualized follow-up.

Adequate calcium and vitamin D are important for bone health, but they may not be sufficient to prevent significant aromatase inhibitor-associated bone loss. Patients with high fracture risk may require prescription treatment in addition to nutritional support and exercise.

Walking supports physical activity, balance, and general health. However, a broader program that includes appropriate resistance training and balance exercises may provide additional benefits. Exercise alone may not prevent osteoporosis in patients at high risk of fractures.

Yes. Osteoporosis usually develops without obvious symptoms. Many people discover they have low bone density through routine testing rather than pain. This is why bone density monitoring is recommended during aromatase inhibitor treatment.

Existing osteoporosis does not necessarily prevent treatment with an aromatase inhibitor. The oncology team may recommend bone-protective medication, nutritional assessment, fall prevention, and closer monitoring. Treatment should be individualized based on fracture risk and cancer-related considerations.

Yes. Both are established options for selected patients receiving aromatase inhibitors. The choice depends on bone density, fracture risk, kidney function, other medical conditions, and treatment goals. Denosumab must not be stopped without a follow-on plan because discontinuation can increase vertebral fracture risk.

Aromatase inhibitors are an important part of treatment for many women with hormone receptor-positive breast cancer. Their ability to reduce estrogen helps lower the risk of cancer recurrence, but it can also place additional strain on the skeleton.

The challenge is that bone loss rarely announces itself. A patient may feel healthy and active while gradually losing bone density over several years.

Fortunately, osteoporosis and fractures are not inevitable consequences of breast cancer hormone therapy.

Early bone density testing, adequate calcium and vitamin D, regular weight-bearing and strengthening exercises, and appropriate osteoporosis medications can make a meaningful difference.

For patients at higher risk, treatments such as bisphosphonates and denosumab offer additional protection against excessive bone loss.

The most important step is to make bone health a routine part of oncology care, beginning when aromatase inhibitor therapy is prescribed and continuing throughout treatment.

Protecting bones while treating breast cancer is not an either-or decision. With appropriate monitoring and individualized care, many patients can continue effective hormone therapy while reducing their risk of osteoporosis, fractures, and long-term mobility problems.

References:

Medical Disclaimer: This article is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Patients should consult their oncologist or other qualified healthcare professional before changing breast cancer medications, taking supplements, or starting osteoporosis treatment.